Gå direkte til indholdet

Beta-talassæmi intermedia og minor

Understøttende behandling

Jernkelerende behandling

Iron out for nontransfused thalassemia. (åbner nyt vindue)

Marks PW.

Kilde‎: Blood 2012;120(5):928-9.

Indekseret‎: PubMed 22859709

DOI‎: 10.1182/blood-2012-06-433227

https://www.ncbi.nlm.nih.gov/pubmed/22859709 (åbner nyt vindue)

Iron overload in β-thalassemia intermedia: an emerging concern. (åbner nyt vindue)

Musallam KM, Cappellini MD, Taher AT.

Kilde‎: Curr Opin Hematol 2013;20(3):187-92.

Indekseret‎: PubMed 23426199

DOI‎: 10.1097/MOH.0b013e32835f5a5c

https://www.ncbi.nlm.nih.gov/pubmed/23426199 (åbner nyt vindue)

Kosttilskud og anden understøttende behandling

Treatment with bosentan in a patient with thalassemia intermedia and pulmonary arterial hypertension. (åbner nyt vindue)

Anthi A, Tsangaris I, Hamodraka ES, Lekakis J, Armaganidis A, Orfanos SE.

Kilde‎: Blood 2012;120(7):1531-2.

Indekseret‎: PubMed 22899478

DOI‎: 10.1182/blood-2012-04-422568

https://www.ncbi.nlm.nih.gov/pubmed/22899478 (åbner nyt vindue)

Prevalance of iron deficiency in thalassemia minor: a study from tertiary hospital. (åbner nyt vindue)

Dolai TK, Nataraj KS, Sinha N, Mishra S, Bhattacharya M, Ghosh MK.

Kilde‎: Indian J Hematol Blood Transfus 2012;28(1):7-9.

Indekseret‎: PubMed 23449336

DOI‎: 10.1007/s12288-011-0088-9

https://www.ncbi.nlm.nih.gov/pubmed/23449336 (åbner nyt vindue)

Therapeutic roles of curcumin: lessons learned from clinical trials. (åbner nyt vindue)

Gupta SC, Patchva S, Aggarwal BB.

Kilde‎: AAPS J 2013;15(1):195-218.

Indekseret‎: PubMed 23143785

DOI‎: 10.1208/s12248-012-9432-8

https://www.ncbi.nlm.nih.gov/pubmed/23143785 (åbner nyt vindue)

Vitamin E supplement improves erythrocyte membrane fluidity of thalassemia: an ESR spin labeling study. (åbner nyt vindue)

Sutipornpalangkul W, Morales NP, Unchern S, Sanvarinda Y, Chantharaksri U, Fucharoen S.

Kilde‎: J Med Assoc Thai 2012;95(1):29-36.

Indekseret‎: PubMed 22379738

https://www.ncbi.nlm.nih.gov/pubmed/22379738 (åbner nyt vindue)

Deferasirox demonstrates a dose-dependent reduction in liver iron concentration and consistent efficacy across subgroups of non-transfusion-dependent thalassemia patients. (åbner nyt vindue)

Taher AT, Porter JB, Viprakasit V, Kattamis A, Chuncharunee S, Sutcharitchan P, Siritanaratkul N, Galanello R, Karakas Z, Lawniczek T, Habr D, Ros J, Zhang Y, Cappellini MD.

Kilde‎: Am J Hematol 2013;88(6):503-6.

Indekseret‎: PubMed 23553596

DOI‎: 10.1002/ajh.23445

https://www.ncbi.nlm.nih.gov/pubmed/23553596 (åbner nyt vindue)